0.2120SEK-7.02%Mkt Cap: 182.59M SEKP/E: —Last update: 2026-06-01
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical developmen…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap182.59M SEK
Enterprise Value173.16M SEK
Revenue (TTM)2.28M SEK
Gross Profit2.28M SEK
Net Income (TTM)-48.56M SEK
Revenue/Share0.0030 SEK
Last Price0.2120 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-3.76
EV/Revenue75.88
P/S86.05
P/B-38.00
EPS (TTM)-0.07
EPS (Forward)—
52W Range
0.20502% of range0.5340
52W High0.5340 SEK
52W Low0.2050 SEK
Profitability
Gross Margin100.00%
Oper. Margin-3758.07%
EBITDA Margin0.00%
Profit Margin-2128.13%
ROE920.99%
ROA-167.32%
Growth
Revenue Growth-61.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-41.62M SEK
CapEx (TTM)—
FCF Margin-1111.48%
FCF Yield-13.89%
Net Debt-23.21M SEK
Net Debt/EBITDA0.50
Balance Sheet
Debt/Equity-3.79
Current Ratio0.84
Quick Ratio0.79
Book Value/Sh-0.0060 SEK
Cash/Share0.0270 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.861.27M
Float399.50M
Insiders7.36%
Institutions65.64%
Technical
SMA 500.2543 (-16.6%)
SMA 2000.3081 (-31.2%)
Beta2.02
S&P 52W Chg27.70%
Avg Vol (30d)407.52K
Avg Vol (10d)435.48K
Technical Indicators
RSI (14)41.3
MACD-0.0035
MACD Signal-0.0025
MACD Hist.-0.0010
BB Upper0.2716 SEK
BB Middle0.2446 SEK
BB Lower0.2176 SEK
BB Width22.11%
ATR (14)0.0257 SEK
Vol Ratio (20d)4.12x